Intermittent Hemodialysis Fails Noninferiority Test in Acute Kidney Injury: NEJM
A multicenter, open label, randomized, noninferiority clinical trial assessing kidney replacement therapies in ICU patients has defined important safety limits in managing acute organ dysfunction. In the study it was found that in critically ill adults with acute kidney injury with indications for kidney replacement therapy, intermittent hemodialysis as an initial strategy was not found to be non-inferior to continuous renal-replacement therapy (CRRT) for major adverse kidney outcomes at 90 days and was linked with increased mortality. The study was published in The New England Journal of Medicine by Stephane G. and colleagues.
For direct comparison of clinical outcomes among the initial modalities, an open-labeled, multicenter, noninferiority trial was carried out in the tertiary centers' intensive care units. Critically ill adults who had acute kidney injury and fulfilled the clinical indications for renal replacement therapy were randomly allocated in a ratio of 1:1 to undergo either intermittent hemodialysis or continuous renal-replacement therapy as the initial modality. In total, 554 subjects were randomized to one of the initial modalities: 272 in intermittent group and 282 in continuous group.
Of these patients, 535 subjects, 260 subjects in intermittent group, and 275 subjects in continuous group made up the final study population. The primary endpoint of the study was the occurrence of a major adverse kidney event defined as death, dependence on renal-replacement therapy, or the persistently elevated serum creatinine levels higher by more than 25% as compared with the baseline, by day 90.
Key findings:
- The study was stopped early due to sequential interim analyses indicating a sustained and statistically significant increase in mortality rates in the intermittent hemodialysis group among 535 intention-to-treat patients.
- The number of major adverse kidney events up to day 90 was 203 (78.1%) in the intermittent hemodialysis group, while 197 (71.6%) of patients experienced such events in the CRRT group (adjusted absolute risk difference, 6.28 percentage points; 95% CI, −1.22 to 13.79), with failure to meet the noninferiority margin.
- The all-cause death rate by day 90 in the intermittent hemodialysis group was 164 patients (63.1%), while 147 patients (53.5%) died in the CRRT group.
- The Kaplan-Meier estimate of 90-day mortality was 63.3% and 53.6%, respectively, which represented a statistically significant increase in mortality rates (hazard ratio, 1.30; 95% CI, 1.04 to 1.63).
- Hypotension was the most common clinical complication associated with acute kidney injury or the treatment method, occurring in 179 (68.8%) and 183 (66.5%) patients in the intermittent and continuous groups, respectively.
In summary, multicenter randomized trial results indicate that intermittent dialysis therapy is not non-inferior but actually shows higher mortality rate during the first 90 days in critically ill adults experiencing acute kidney injury. It should also be noted that findings of the paper point to the fact that modalities continuous in their nature should be used first when starting renal replacement therapy.
Reference:
Gaudry, S., Boubaya, M., Louis, G., Chaïbi, K., de Montmollin, E., Bohé, J., Desgrouas, M., Devautour, C., Joseph, A., Mégarbane, B., Camus, C., Bailly, P., Lambour, A., Arrestier, R., Jaber, S., Robine, A., Chudeau, N., Chevrel, G., La Combe, B., … Dreyfuss, D. (2026). Intermittent or continuous renal-replacement therapy in acute kidney injury. New England Journal of Medicine, 395(17), 1677–1690. https://doi.org/10.1056/nejmoa2608397
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.